MX2022009584A - Anticuerpos anti-hepsina y usos de los mismos. - Google Patents

Anticuerpos anti-hepsina y usos de los mismos.

Info

Publication number
MX2022009584A
MX2022009584A MX2022009584A MX2022009584A MX2022009584A MX 2022009584 A MX2022009584 A MX 2022009584A MX 2022009584 A MX2022009584 A MX 2022009584A MX 2022009584 A MX2022009584 A MX 2022009584A MX 2022009584 A MX2022009584 A MX 2022009584A
Authority
MX
Mexico
Prior art keywords
hepsin antibodies
hepsin
antibodies
methods
diagnose
Prior art date
Application number
MX2022009584A
Other languages
English (en)
Spanish (es)
Inventor
Blake P Johnson
Timothy J O''brien
Original Assignee
Navaux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navaux Inc filed Critical Navaux Inc
Publication of MX2022009584A publication Critical patent/MX2022009584A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022009584A 2020-02-05 2021-02-03 Anticuerpos anti-hepsina y usos de los mismos. MX2022009584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970626P 2020-02-05 2020-02-05
PCT/US2021/016409 WO2021158660A2 (en) 2020-02-05 2021-02-03 Anti-hepsin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2022009584A true MX2022009584A (es) 2022-10-07

Family

ID=77200525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009584A MX2022009584A (es) 2020-02-05 2021-02-03 Anticuerpos anti-hepsina y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230236192A1 (enExample)
EP (1) EP4100062A4 (enExample)
JP (1) JP2023512782A (enExample)
KR (1) KR20220137696A (enExample)
CN (1) CN115427075A (enExample)
AU (1) AU2021215999A1 (enExample)
BR (1) BR112022015523A2 (enExample)
CA (1) CA3169809A1 (enExample)
IL (1) IL295258A (enExample)
MX (1) MX2022009584A (enExample)
WO (1) WO2021158660A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259819A1 (en) * 2024-06-11 2025-12-18 Navaux, Inc. Anti-hepsin antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
US8383351B2 (en) * 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
WO2010082034A1 (en) * 2009-01-16 2010-07-22 University Of Exeter Antibody
RU2559533C2 (ru) * 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN102093479B (zh) * 2010-11-29 2012-10-03 侯宗柳 抗人血管内皮生长因子受体2的重组嵌合抗体
EP2721417A4 (en) * 2011-06-17 2015-05-06 Univ Arkansas NEW MARKERS FOR EARLY DIAGNOSIS OF EGG CANCER, MONITORING DURING THE CORRESPONDING THERAPY AND NEW THERAPY OPTIONS DURING AND AFTER THE CORRESPONDING CHEMOTHERAPY
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

Also Published As

Publication number Publication date
WO2021158660A2 (en) 2021-08-12
KR20220137696A (ko) 2022-10-12
BR112022015523A2 (pt) 2022-09-27
JP2023512782A (ja) 2023-03-29
EP4100062A2 (en) 2022-12-14
CN115427075A (zh) 2022-12-02
US20230236192A1 (en) 2023-07-27
AU2021215999A1 (en) 2022-09-01
CA3169809A1 (en) 2021-08-12
WO2021158660A3 (en) 2021-09-23
IL295258A (en) 2022-10-01
EP4100062A4 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
CL2024003552A1 (es) Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
MX2024000611A (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso.
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
BR112022001416A2 (pt) Populações de células t gama delta ex vivo
MX2023005081A (es) Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.
ZA202309516B (en) Anti-ccr8 antibodies
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
AU2020212767A8 (en) Combined pharmaceutical composition for treating tumor
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
MX2022013311A (es) Anticuerpo biespecifico anti-cd73-anti-pd-1 y uso del mismo.
JOP20210333A1 (ar) جسم مضاد لـ EphA4
WO2019224713A3 (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
CA3207182A1 (en) T cell therapy
ZA202305072B (en) Cd1a antibodies and uses thereof
JOP20220320B1 (ar) أجسام مضادة لـ pd-1
MX2022009584A (es) Anticuerpos anti-hepsina y usos de los mismos.
WO2022170008A3 (en) Anti-il1rap antibodies